Oncology
Page 4 • 12 itemsGlobal oncology market intelligence for pharma BD, investors, and analysts. Track drug approvals, clinical trials, and competitive landscapes.
Ipsen Receives EU Approval for Ojemda (Tovorafenib) to Treat Pediatric Brain Cancer with BRAF Mutations
Ipsen secures conditional EU marketing authorization for Ojemda (tovorafenib) to treat pediatric low-grade glioma with BRAF alterations in patients 6 months and older.
RedHill's Opaganib Shows Promise in Neuroblastoma and Triple-Negative Breast Cancer Studies at AACR 2026
RedHill's opaganib demonstrates enhanced efficacy in neuroblastoma chemotherapy combinations and improved anti-tumor immunity in TNBC preclinical studies.
RedHill's Opaganib Shows Promise in Neuroblastoma and Triple-Negative Breast Cancer Studies at AACR 2026
RedHill's opaganib demonstrates enhanced efficacy in neuroblastoma chemotherapy combinations and improved anti-tumor immunity in preclinical cancer studies.
Lung Cancer Therapeutics Market to Hit $142.3 Billion by 2036 as Precision Medicine Drives 11.8% Growth
Global lung cancer therapeutics market projected to grow from $46.8B to $142.3B by 2036, driven by precision medicine and immunotherapy advances.
Ipsen's Ojemda (Tovorafenib) Becomes First Targeted Therapy for Pediatric Brain Tumors in EU
Ipsen's Ojemda receives EU approval as first targeted therapy for pediatric low-grade glioma, addressing critical unmet need in rare brain tumors.
Kelun-Biotech's Sac-TMT Cancer Drug Selected for Three ASCO 2026 Oral Presentations
Kelun-Biotech announces three clinical studies of sac-TMT selected for oral presentations at ASCO 2026, highlighting progress in cancer treatment.
GRAIL's Galleri Cancer Detection Test Shows Major Results in 174,000-Patient Studies at ASCO 2026
GRAIL presents breakthrough NHS-Galleri and PATHFINDER 2 trial data for multi-cancer early detection test at ASCO 2026, covering 174,000+ participants.
Karyopharm Phase 3 SENTRY Trial Results Selected for ASCO 2026 Late-Breaking Presentation in Myelofibrosis
Karyopharm's Phase 3 SENTRY trial in myelofibrosis earns prestigious late-breaking oral presentation slot at ASCO 2026, signaling potential breakthrough results.
Allogene Therapeutics Expands Cemacabtagene Ansegedleucel Phase 2 ALPHA3 Trial to South Korea and Australia
Allogene Therapeutics receives regulatory clearance to expand pivotal Phase 2 ALPHA3 trial of cemacabtagene ansegedleucel to South Korea and Australia markets.
Biocon Receives Health Canada Approval for Denosumab Biosimilars Bosaya and Vevzuo
Health Canada approves Biocon's denosumab biosimilars Bosaya and Vevzuo as alternatives to Prolia and Xgeva for osteoporosis and cancer treatment.
EGFR Inhibitors Market Access in Europe: Launch Strategies & Challenges
This article delves into the market access strategies and challenges for EGFR inhibitors in Europe, crucial for advancing lung cancer therapies.
PRAC Safety Signal Assessment: Insights on Bispecific Antibodies in Hematologic Malignancies
This article delves into PRAC's assessment of safety signals related to bispecific antibodies, focusing on their efficacy and safety in treating hematologic malignancies.